Plain-English translation of NCT07283705 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called to see if it works better when combined with standard chemotherapy for pancreatic cancer patients who have a specific genetic mutation (called MTAP deletion). The study includes three groups of patients with different stages of pancreatic cancer — those who might be candidates for surgery, those with locally advanced disease, and those with cancer that has spread to other parts of the body. Researchers want to understand if this medication can help slow or shrink the cancer and improve how long patients survive.
Pancreatic cancer is one of the most difficult cancers to treat, and current chemotherapy options have limited effectiveness for many patients. This trial exists because researchers have identified that some pancreatic cancers have a genetic weakness (MTAP deletion) that this new medication might be able to target, potentially offering patients a more effective treatment option.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you will receive the new medication combined with standard chemotherapy (either as a combination of and , or , depending on your cancer stage). Treatment typically lasts 4–6 months, followed by continued treatment with the medication alone as long as your cancer does not worsen. You will have regular clinic visits for blood tests, imaging scans, and physical exams to monitor how well the treatment is working and to watch for any side effects. The study team will carefully track your safety and how your cancer responds to help determine if this new approach is beneficial.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Collaborators
Bristol-Myers Squibb
Enrollment target
~60 participants
Started
May 2026
Primary completion
October 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Maria P Morelli, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.